ATB.RO Antibiotice Ia
- Market cap
- RON 1.29B
- P/E
- 191.6x
- P/B
- 1.38x
- ROE
- 3.5%
- Dividend yield
- 1.24%
- Fundamental score
- 2.7/5
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Jun 2026.
Is ATB.RO undervalued?
Graham numberThe Graham number of Antibiotice Ia cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Antibiotice Ia fundamental analysis
12 of 22 checks passedROE 0/2
Low return on equity (3.5%), below 10%.
ROA 0/1
Return on assets (2.1%) is below the industry median (3.7%).
Profit Consistency 2/2
Profitable for 6 consecutive years.
Earnings Growth 5Y 1/1
Earnings per share grew over the past 5 years.
Earnings Acceleration 0/1
Last year's EPS growth (-49.3%) is not above the 5-year average (14.4% a year).
Earnings Growth vs Industry 0/1
Last year's EPS growth (-49.3%) is below the industry median (24.7%).
Revenue Growth 2/2
Revenue grew 10.1% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 2/2
Low debt to equity (6.3%), 40% or less.
Debt Trend 1/1
Debt to equity has not risen over the past 5 years.
Debt Coverage 1/1
Operating cash flow covers 20% of total debt.
Interest Coverage 1/1
EBIT is 8.4x against interest expense, well covered.
PE vs Market 0/1
PE (191.6x) is above the market median (18.3x).
PE vs Industry 0/1
PE (191.6x) is above the industry median (19.0x).
PBV 1/1
Price to book (1.4x) is below the industry median (2.6x).
Graham Number 0/1
The price is above the Graham number (PE x PB = 264.5, limit 22.5).
PEG 0/1
PEG on 5-year earnings growth is 13.28, above 1.
Dividend Yield 1/2
Dividend yield (1.2%) is above the bottom 25% of dividend payers in the market.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 1/1
Payout ratio is 30.8%, covered by earnings.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Antibiotice Ia stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Antibiotice Ia
Antibiotice S.A. produces and sells medicinal products in Romania and internationally. The company provides generic prescription medicines comprising anti-infectives, including drugs for the treatment of tuberculosis, as well as cardiovascular drugs, digestive tract and metabolism class, preparations for the treatment of gynecological diseases, and dermatological and central nervous system preparations; generic non-prescription medicines, including food supplements, cosmetic…
Full company profileAntibiotice Ia financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Antibiotice Ia annual financial statements (RON; K = thousand, M = million, B = billion, T = trillion)
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 340M | 366M | 484M | 601M | 675M | 645M | 635M |
| Gross Profit | 239M | 230M | 332M | 409M | 452M | 423M | 416M |
| Operating Income | 42.6M | 29.4M | 70.9M | 98.4M | 104M | 61.2M | 52.6M |
| EBITDA | - | - | 94.2M | 124M | 153M | 118M | 99.8M |
| Net Income | 26.4M | 29.9M | 51.5M | 81.1M | 102M | 51.8M | 32.8M |
| EPS | 0.04 | 0.04 | 0.08 | 0.12 | 0.15 | 0.08 | 0.05 |
| Balance Sheet | |||||||
| Total Assets | 863M | 895M | 856M | 1.14B | 1.28B | 1.39B | 1.55B |
| Total Liabilities | 286M | 290M | 215M | 292M | 385M | 460M | 624M |
| Shareholders' Equity | 577M | 605M | 641M | 847M | 894M | 932M | 931M |
| Cash & Short-term Investments | 6.33M | 2.11M | 1.73M | 1.81M | 2.68M | 9.94M | 3.08M |
| Cash Flow | |||||||
| Operating Cash Flow | - | - | 116M | 122M | 95.1M | 72.4M | 22.7M |
| Capital Expenditure | 48.0M | 29.1M | 39.9M | 98.0M | 116M | 143M | 143M |
| Free Cash Flow | 46.1M | 15.4M | 65.7M | 24.4M | -21.0M | -70.2M | -120M |
| Ratios | |||||||
| ROE | 4.6% | 4.9% | 8.0% | 9.6% | 11.4% | 5.6% | 3.5% |
| ROA | 3.1% | 3.3% | 6.0% | 7.1% | 8.0% | 3.7% | 2.1% |
| Net Profit Margin | 7.8% | 8.2% | 10.6% | 13.5% | 15.1% | 8.0% | 5.2% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Antibiotice Ia dividends
- Dividend yield
- 1.24%
- Forward dividend
- 0.04 RON
- Payout ratio
- 30.8%
- Ex-dividend date
- Oct 15, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | RON 15.9M | 0.02 | 30.8% |
| 2024 | RON 48.2M | 0.07 | 47.1% |
| 2023 | RON 5.43M | 0.01 | 6.7% |
| 2022 | RON 2.00M | 0.00 | 3.9% |
| 2021 | RON 2.10M | 0.00 | 7.0% |
| 2020 | RON 18.2M | 0.03 | 68.8% |
| 2014 | - | - | - |
| 2013 | - | - | - |
| 2012 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.18192:1 on Jul 11, 2013.
Who owns Antibiotice Ia
- Insiders 58.05%
- Institutions 14.22%
- Public & others 27.73%
- Shares outstanding 671M
- Free float 228M
Antibiotice Ia company profile
- Company name
- Antibiotice Ia
- Ticker
- ATB.RO
- ISIN
- ROATBIACNOR9
- Exchange
- Bucharest Stock Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 1,354
- Fiscal year end
- September
- Address
- 1 Valea Lupului Street, Iasi, Romania, 707410
- Phone
- 40 23 220 9000
- Website
- antibiotice.ro
About Antibiotice Ia
Antibiotice S.A. produces and sells medicinal products in Romania and internationally. The company provides generic prescription medicines comprising anti-infectives, including drugs for the treatment of tuberculosis, as well as cardiovascular drugs, digestive tract and metabolism class, preparations for the treatment of gynecological diseases, and dermatological and central nervous system preparations; generic non-prescription medicines, including food supplements, cosmetics, and medical devices; active substances; biofertilizers; biocides for disinfecting surfaces and hands; and veterinary medicines. Its products are available in the form of sterile injectable powders, capsules, tablets, ointments, gels, creams, pessaries, and suppositories. It offers active pharmaceutical ingredients. The company exports its products to approximately 70 countries. Antibiotice S.A. was founded in 1955 and is headquartered in Iasi, Romania.
Antibiotice Ia management
8- Mr. Ioan NaniCEO & Director · born 1959
- Ms. Paula-Luminita ComanExecutive Director of Financial & CFO · born 1968
- Engineer Eugen Florin OsadetEngineering & Investment Director · born 1957
- Engineer Cornelia MoraruInvestors Relation Officer and Executive Director of Technical & Production · born 1966
- Ms. Liviu VatavuExecutive Director of Legal, Human Resources & Administration · born 1971
- Mr. Ovidiu BatagaExecutive Director of National Sales · born 1978
- Ms. Stefania AlexandruDeputy General Manager of Planning, Portfolio Management & Sales · born 1984
- Bogdan Mircea BabiciDeputy General Manager of Finance & Corporate Governance · born 1977